Aim: The aim of the present study was to compare demographic and laboratory features among patients diagnosedwith myeloma nephropathy and compare efficiency of various therapies in improving kidney functions. Material and Methods: The medical records of 16 patients (12 males, 4 females, mean age was 56±17 years), whowere followed at our clinic due to myeloma nephropathy, were retrospectively reviewed. Demographic features andlaboratory parameters of the patients were evaluated. The presence of acute kidney injury was determined accord- ing to KDIGO criteria. As a chemotherapy protocol, 10 cases received VAD and 5 cases received MP protocols. Thepatients, who achieved at least 25% reduction in serum creatinine level or suspended hemodialysis, were consideredresponders. A p value <0.05 was considered statistically significant. Results: The most frequent presentation was bone pain (particularly lumbar pain) occurring in 10 patients (62.5%).All patients had anemia, and the reason triggering kidney injury was hyperurisemia in 13 patients (81.2%), analgesicoveruse in 9 patients (56.2%), hypercalcemia in 6 patients (37.5%), dehydration in 6 patients (37.5%), infections in 5patients (31.2%), and hemorrhage in 1 patient (6.2%). Age, gender, stage, type of myeloma, erythrocyte sedimenta- tion rate, CRP, LDH, beya-2 microglobulin, creatinine, total protein, albumin, hemoglobin, uric acid, sodium, amountof proteinuria, and chemotherapy protocol did not significantly differ between patients that exhibited improvement inkidney functions versus patients that exhibit no improvement in kidney functions (P>0.05). Serum calcium level wassignificantly higher in responders (13.5±1.7 mg/dl) compared to non-responders (9.8±1.1 mg/dl) (P<0.05).Discussion: It was reported that AKI was improved by supportive medical therapy, hemodialysis if indicated, andafter chemotherapy in at least half of the patients with myeloma nephropathy. In the present patient group, kidney functions were improved with treatment in 7 patients (43.7%). Only one patientthat showed improvement in kidney functions underwent hemodialysis, and the remaining six patients did not requirehemodialysis.Further improvement in kidney functions can be obtained if lower calcium levels can be achieved with treatment.In the present study, patients with higher serum calcium levels (13.5±1.7 mg/dl) that received therapy to reduce se- rum calcium to normal levels achieved higher improvement in AKI compared to those with normal calcium levels(9.8±1.1 mg/dl) (P<0.05). In conclusion, nephropathy, a common finding in multiple myeloma, significantly increases mortality and morbidity,and more emphasis must be placed on measures to prevent kidney injury.